Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones [Yahoo! Finance]
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
Microbot Medical (NASDAQ:MBOT) was upgraded by analysts at Roth Capital to a "strong-buy" rating. They now have a $5.50 price target on the stock.
Microbot Medical (NASDAQ:MBOT) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Microbot Medical (NASDAQ:MBOT) had its "buy" rating reaffirmed by analysts at HC Wainwright.